ABT’s Xience Xpedition is an incremental improvement; it’s not a big deal from a business standpoint insofar as the Xience family was already the market leader.
Of more consequence to ABT’s top and bottom lines will be the launch of the bioresorbable drug-eluting stent in the US, pending the reporting of data from the US pivotal study.
Market Data 
Markets 
AI
